This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): PTH 1-34, teriparatide [rDNA origin] injection, Forsteo (EU), LY333334
Description: Forteo (teriparatide) is a recombinantly expressed peptide that includes the N-terminal, 34-residue, biologically active region (residues 1-34) of human parathyroid hormone (PTH).
Deal Structure: In January 2006, Eli Lilly and Alkermes announced a collaboration on the development and commercializiation of an inhaled form of parathyroid hormone. Under the agreement, Alkermes would primarily work on formulation testing and device development and in return would receive royalties based on product sales.
In July 2011, Eli Lilly and Janssen announced that they will conduct and fund the evaluation of additional orthopedic uses for Forteo. In addition to the development component of the agreement, the collaboration includes the co-promotion of Forteo to orthopedic surgeons in the US and in select OUS countries.
Partners: Johnson & Johnson
Additional information available to subscribers only: